This is a partnered post with Galderma Laboratories, L.P. the maker of Oracea® (doxycycline, USP) 40 mg* Capsules, Soolantra® (ivermectin) Cream, 1% and Mirvaso® (brimonidine) Gel, 0.33%**. All thoughts and opinions expressed are my own.
One thing that is important to many people, especially women is their skin. I know my skin has always been something I have tried to take care of. When I used to have acne as a teen I would conceal the acne with makeup because who likes going to school with pimples?
Similar to acne, rosacea is a highly-visible skin condition that occurs in both men and women, affecting the face. Rosacea is a chronic inflammatory disorder that often begins as redness in the cheeks, nose, chin, or forehead and can be triggered by simple things like changes in the temperature or certain foods and drinks. Rosacea can also be triggered by stress!
In a survey performed by the National Rosacea Society that include over 500 people with rosacea, 42% reported feeling sad or depressed by the appearance of their skin.
While there are those out there concealing their acne with makeup, there are also those out there who are also covering their rosacea with makeup instead of trying to treat it. For those that suffer from rosacea and use makeup to cover it up, Galderma wants you to Break Up with Your Makeup! They want you to know that there are treatment options available like Soolantra® (ivermectin) Cream, 1%, Oracea® (doxycycline, USP) 40 mg* Capsules, and Mirvaso® (brimonidine) Gel, 0.33%**.
For more information, check out the Break Up with Your Makeup campaign!
Important Safety Information for Oracea® Capsules
Indication: ORACEA® (doxycycline, USP) 40 mg* Capsules are indicated for the treatment of only
inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established.
*30 mg immediate release & 10 mg delayed release beads
Important Safety Information for Soolantra® Cream
Indication: SOOLANTRA® (ivermectin) Cream, 1%, is indicated for the treatment of inflammatory lesions of rosacea. Not for oral, ophthalmic or intravaginal use. Adverse Events: In clinical trials with SOOLANTRA® Cream, the most common adverse reactions (incidence ≲ 1%) included skin burning sensation and skin irritation.
Important Safety Information for Mirvaso® Gel
Indication: Mirvaso® (brimonidine) topical gel, 0.33%** is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions ( ≳ 1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.
**Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatchor call 1-800-FDA-1088.
All trademarks are the property of their respective owners.
Leave a Reply